March 1, 2022

A noninvasive ultrasound treatment for Parkinson’s disease that was tested in a pivotal trial led by University of Maryland School of Medicine (UMSOM) researchers is now broadly available at the University of Maryland Medical Center. The device, called Exablate Neuro, was approved in November by the U.S. Food and Drug Administration to treat advanced Parkinson’s disease on one side of the brain. The approval was based on findings from the UMSOM clinical trial and effectively expands access to focused ultrasound beyond clinical trial participation.

Learn more here.